Skip to main content
Immuron Ltd logo

Immuron Ltd — Investor Relations & Filings

Ticker · IMRN ISIN · US45254U1016 LEI · 529900ZIDI5C9C9TTI91 ASX Manufacturing
Filings indexed 1,602 across all filing types
Latest filing 2023-09-27 Regulatory Filings
Country AU Australia
Listing ASX IMRN

About Immuron Ltd

https://www.immuron.com.au

Immuron Ltd. is a clinical and commercial-stage biopharmaceutical company focused on developing and commercializing a novel class of orally delivered, specifically targeted polyclonal antibodies. The company's proprietary technology platform is based on polyclonal immunoglobulins (IgG) derived from hyper-immune bovine colostrum to address unmet medical needs, primarily related to gastrointestinal and enteric diseases. Its commercialized products include Travelan®, for reducing the risk of travelers' diarrhea, Protectyn®, for supporting gut and liver function, and ProIBS®, for relieving symptoms of Irritable Bowel Syndrome. Immuron's clinical pipeline includes therapeutic candidates for infectious diseases such as Clostridioides Difficile and Vancomycin-Resistant Enterococci.

Recent filings

Filing Released Lang Actions
Appendix 4G 12 pages 355.5KB
Regulatory Filings
2023-09-27 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2023-09-13 English
Immuron achieves record monthly Travelan sales 3 pages 280.2KB
Regulatory Filings
2023-09-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2023-09-11 English
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright 15 pages 2.0MB
Regulatory Filings
2023-09-10 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2023-08-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.